{
    "clinical_study": {
        "@rank": "117565", 
        "arm_group": {
            "arm_group_label": "AT1001 150 mg", 
            "arm_group_type": "Experimental", 
            "description": "Each subject will receive a single oral dose of AT1001 150 mg administered orally with 240 mL room temperature water after at least a 4-hour fast"
        }, 
        "brief_summary": {
            "textblock": "This study will assess the safety, tolerability, and pharmacokinetics (PK) study of a single\n      dose of  150 mg AT1001 (migalastat HCl, GR181413A) administered orally to healthy subjects\n      with normal renal function and to subjects with mild, moderate, and severe renal impairment."
        }, 
        "brief_title": "Safety and Pharmacokinetics of AT1001 (Migalastat HCl) in Healthy Subjects and Subjects With Impaired Renal Function", 
        "completion_date": {
            "#text": "April 2012", 
            "@type": "Actual"
        }, 
        "condition": "Fabry Disease", 
        "condition_browse": {
            "mesh_term": [
                "Fabry Disease", 
                "Renal Insufficiency"
            ]
        }, 
        "detailed_description": {
            "textblock": "This will be an open-label, non-randomized, multiple-center, sequential group, safety,\n      tolerability, and PK study of a single dose of  AT1001 (migalastat HCl, GR181413A)\n      administered orally as a 150 mg dose in fasted healthy control male and female subjects with\n      normal renal function compared to mild, moderate, and severe renally-impaired subjects\n      (classified by level of creatinine clearance [CLcr] as determined by the Cockcroft-Gault\n      formula).\n\n      Screening will occur from Day -28 to Day -2.  Subjects will check-in to the clinic on Day -1\n      and receive a single oral dose of 150 mg AT1001 on Day 1. Subjects will be discharged from\n      the clinic on Day 2 (if stable as determined by the Investigator) and return for daily\n      visits on Day 3 through Day 6 for a safety assessment and PK sampling.  Subjects will\n      undergo a follow-up visit on Day 7 (+1) and an end of study visit on Day 10 (+1)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria All subjects\n\n          -  males or females aged 18 to 70 years inclusive (subjects with normal renal function,\n             mild or moderate renal impairment), and 18 to 75 years inclusive (subjects with\n             severe renal impairment)\n\n          -  body mass index 18.0 to 40.0 kilogram (kg)/square meter (m^2) inclusive\n\n          -  females who are non-pregnant, non-lactating, or postmenopausal for >=1 year,\n             surgically sterile for >= 90 days, or agree to use approved methods of contraception\n\n          -  males will be sterile or use approved methods of contraception\n\n          -  understands and signs informed consent form Healthy subjects with normal renal\n             function\n\n          -  negative test for selected drugs of abuse (excludes alcohol) at Screening and\n             Check-in\n\n          -  good health with no clinically significant medical history, physical examination,\n             vital signs, or 12-lead ECG\n\n          -  clinical laboratory tests within the reference range or not clinically significant\n\n          -  normal renal function (estimated CLcr >90 mL/min) at Screening Subjects with mild,\n             moderate or severe renal impairment\n\n          -  negative test for selected drugs of abuse (excludes alcohol) at Screening and\n             Check-in or verification of a prescription for a positive test\n\n          -  renal impairment (estimated CLcr <90 mL/min)\n\n          -  evidence of stable renal impairment defined as two separate estimated CLcr values\n             within 25%\n\n          -  clinical laboratory results consistent with their renal condition or of no clinical\n             significance for the study\n\n          -  abnormal laboratory values must not be clinically significant. Anemia secondary to\n             renal disease is acceptable if hemoglobin is \u22659 g/dL and no clinically significant\n             symptoms. Liver enzymes and bilirubin must be below twice the upper normal level\n\n          -  subjects with renal impairment must have stable underlying medical conditions < 90\n             days before study start\n\n          -  stable medication regimen(s) (no new drug(s) or changed dosage(s) <30 days before\n             study drug)\n\n          -  in good general health, allowing for concurrent illnesses associated with chronic\n             kidney disease\n\n        Exclusion Criteria:\n\n        All subjects:\n\n          -  history of hypersensitivity or allergies to any drug, unless approved by the\n             Investigator and reviewed by Sponsor/Medical Monitor\n\n          -  participation in a study with receipt of an investigational drug < 5 half-lives or 30\n             days (whichever is longer) before Check-in\n\n          -  use of alcohol, grapefruit, or caffeine-containing foods or beverages < 72 hours\n             before Check-in, unless approved by the Investigator and reviewed by the\n             Sponsor/Medical Monitor\n\n          -  poor peripheral venous access\n\n          -  whole blood donation < 56 days before dosing or plasma donation < 14 days before\n             dosing\n\n          -  receipt of blood products < 2 months before Check-in\n\n          -  history or presence of any clinically significant abnormal ECG\n\n          -  history of alcoholism or drug addiction < 1 year before Check-in\n\n          -  positive test for HIV antibody, HBsAg or anti-HCV\n\n          -  pregnant or breastfeeding\n\n        Healthy subjects with normal renal function:\n\n          -  use of any tobacco- or nicotine-containing products < 6 months before Check-in\n\n          -  clinically significant (history of or active) cardiac, hepatic, pulmonary, endocrine,\n             neurological, infectious, gastrointestinal, hematologic, oncologic, or psychiatric\n             disease putting the subject at increased risk or could interfere with study\n             objectives\n\n          -  screening laboratory values outside normal range and deemed clinically significant by\n             the Investigator\n\n          -  use of a prescription drug < 14 days of dosing or a non-prescription drug < 7 days\n             before dosing or need of concomitant medication during the study\n\n        Subjects with mild, moderate, or severe renal impairment:\n\n          -  unstable disease (concurrent medical conditions that have changed significantly < 90\n             days)\n\n          -  changes in concomitant prescription medications < 30 days before dosing or expected\n             changes during study\n\n          -  use of new non-prescription medication < 30 days before dosing\n\n          -  renal transplant\n\n          -  acute or chronic non-renal condition limiting the subject's ability to complete\n             and/or participate in the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 8, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01730469", 
            "org_study_id": "116431"
        }, 
        "intervention": {
            "arm_group_label": "AT1001 150 mg", 
            "description": "AT1001 150mg is available as a capsule", 
            "intervention_name": "AT1001 150 mg", 
            "intervention_type": "Drug", 
            "other_name": [
                "migalastat HCl", 
                "GR181413A"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Pharmacokinetics", 
            "GR181413", 
            "Safety", 
            "AT1001", 
            "Migalastat hydrochloride"
        ], 
        "lastchanged_date": "December 17, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Costa Mesa", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92626"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33014"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33169"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32809"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-Label Study to Determine the Safety and Pharmacokinetics of AT1001 in Subjects With Impaired Renal Function and Healthy Subjects With Normal Renal Function (AT1001-015)", 
        "overall_official": {
            "affiliation": "Amicus Therapeutics", 
            "last_name": "Medical Monitor, Clinical Research", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Adverse events will be evaluated from Day 1 to the end of study (Day 10 +1).", 
                "measure": "Number of subjects with adverse events to assess safety and tolerability", 
                "safety_issue": "No", 
                "time_frame": "Day 1 to Day 10 (+1)"
            }, 
            {
                "description": "Clinical laboratory evaluations (hematology, clinical chemistry, urinalysis, Hepatitis A and HIV screen) will be evaluated from screening to the end of the study.", 
                "measure": "Clinical laboratory test values to assess safety and tolerability", 
                "safety_issue": "No", 
                "time_frame": "Day -28 to Day 10 (+1)"
            }, 
            {
                "description": "Vital signs (oral temperature, respiratory rate, and seated blood pressure) will be performed from screening to the end of the study.", 
                "measure": "Vital signs to assess safety and tolerability", 
                "safety_issue": "No", 
                "time_frame": "Day -28 to Day 10 (+1)"
            }, 
            {
                "description": "Physical examination (general appearance, skin, thorax/lungs, cardiovascular and abdomen) will be performed from screening to the end of the study.", 
                "measure": "Physician examination to assess safety and tolerability", 
                "safety_issue": "No", 
                "time_frame": "Day -28 to Day 10 (+1)"
            }, 
            {
                "description": "Electrocardiogram (ECG) measures the electrical activity of the heart and the hearts' rhythm. All subjects will undergo ECG testing.", 
                "measure": "Measure of ECG to assess safety and tolerability", 
                "safety_issue": "No", 
                "time_frame": "Day -28 to Day 10 (+1)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01730469"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Blood samples will be collected at predose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 15, 24, 48, 72, 96, and 120 hours post-dose and the resultant maximum plasma concentration (Cmax) will be measured in subjects with impaired renal function and normal renal function.", 
                "measure": "Maximum observed concentration (Cmax) of AT1001", 
                "safety_issue": "No", 
                "time_frame": "Day 1 to Day 6"
            }, 
            {
                "description": "Blood samples will be collected at predose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 15, 24, 48, 72, 96, and 120 hours post-dose and time to maximum concentration (tmax) will be measured in subjects with impaired renal function and normal renal function.", 
                "measure": "Time to achieve maximum concentration (Tmax) of AT1001", 
                "safety_issue": "No", 
                "time_frame": "Day 1 to Day 6"
            }, 
            {
                "description": "Blood samples will be collected at predose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 15, 24, 48, 72, 96, and 120 hours post-dose and and apparent terminal elimination half-life (t1/2) will be measured in subjects with impaired renal function and normal renal function.", 
                "measure": "Apparent terminal elimination half life (t1/2 ) of AT1001", 
                "safety_issue": "No", 
                "time_frame": "Day 1 to Day 6"
            }, 
            {
                "description": "Blood samples will be collected at predose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 15, 24, 48, 72, 96, and 120 hours post-dose and AUC 0-t will be measured in subjects with impaired renal function and normal renal function", 
                "measure": "Area under the concentration-time curve from time zero to the last measurable concentration (AUC 0-t ) of AT1001", 
                "safety_issue": "No", 
                "time_frame": "Day 1 to Day 6"
            }, 
            {
                "description": "Blood samples will be collected at predose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 15, 24, 48, 72, 96, and 120 hours post-dose and AUC 0-inf will be measured in subjects with impaired renal function and normal renal function", 
                "measure": "Area under the  concentration-time curve extrapolated to infinity (AUC 0-inf) of AT1001", 
                "safety_issue": "No", 
                "time_frame": "Day 1 to Day 6"
            }, 
            {
                "description": "Blood samples will be collected at predose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 15, 24, 48, 72, 96, and 120 hours post-dose and the apparent terminal elimination rate constant will be measured in subjects with impaired renal function and normal renal function", 
                "measure": "Apparent terminal elimination rate constant for AT1001", 
                "safety_issue": "No", 
                "time_frame": "Day 1 to Day 6"
            }, 
            {
                "description": "Blood samples will be collected at predose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 15, 24, 48, 72, 96, and 120 hours post-dose and the oral clearance will be measured in subjects with impaired renal function and normal renal function", 
                "measure": "Oral clearance of AT1001", 
                "safety_issue": "No", 
                "time_frame": "Day 1 to Day 6"
            }, 
            {
                "description": "Blood samples will be collected at predose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 15, 24, 48, 72, 96, and 120 hours post-dose and the oral volume of distribution will be measured in subjects with impaired renal function and normal renal function", 
                "measure": "Oral volume of distribution of AT1001", 
                "safety_issue": "No", 
                "time_frame": "Day 1 to Day 6"
            }
        ], 
        "source": "Amicus Therapeutics", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Amicus Therapeutics", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2011", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}